Shenyang Sinqi Pharmaceutical Company Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
1,763
- Stock Symbol
-
300573
- Share Price
-
$25.13
- (As of Thursday Closing)
Shenyang Sinqi Pharmaceutical Company General Information
Description
Shenyang Xingqi Pharmaceutical Co Ltd is a pharmaceutical company. It produces and sells opthalmic products. Its products include anti-bacterial products, corneal products, anti-inflammation products, anti-allergic, antifungal & among others.
Contact Information
- 68 Sishui Street
- Dongling District
- Shenyang, Liaoning 110163
- China
Shenyang Sinqi Pharmaceutical Company Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $25.13 | $25.13 | $11.59 - $26.16 | $3.13B | 125M | 2.53M | $0.22 |
Shenyang Sinqi Pharmaceutical Company Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 2,487,879 | 1,520,486 | 1,761,306 | 1,210,408 |
| Revenue | 191,455 | 185,589 | 159,192 | 99,685 |
| EBITDA | 26,682 | 44,412 | 48,937 | 22,257 |
| Net Income | 27,104 | 31,433 | 30,153 | 12,735 |
| Total Assets | 262,927 | 258,424 | 264,640 | 153,595 |
| Total Debt | 8,471 | 2,002 | 17,458 | 18,073 |
Shenyang Sinqi Pharmaceutical Company Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Shenyang Sinqi Pharmaceutical Company Patents
Shenyang Sinqi Pharmaceutical Company Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020394743-A1 | Weak alkaline cabazitaxel derivative and formulation thereof | Pending | 03-Dec-2019 | 0000000000 | |
| EP-4071141-A1 | Weak alkaline cabazitaxel derivative and formulation thereof | Inactive | 03-Dec-2019 | 0000000000 | |
| US-20220378735-A1 | Cabazitaxel weakly- alkaline derivative and formulation thereof | Pending | 03-Dec-2019 | 0000000000 | |
| EP-3998254-A4 | 2-aminopyrimidine compound and application thereof | Pending | 04-Jul-2019 | 0000000000 | 0 |
| EP-3998254-A1 | 2-aminopyrimidine compound and application thereof | Pending | 04-Jul-2019 | C07D413/14 |
Shenyang Sinqi Pharmaceutical Company Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Liu Jidong | Shenyang Sinqi Pharmaceutical Company | Chairman | 000 0000 |
Shenyang Sinqi Pharmaceutical Company Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Shenyang Sinqi Pharmaceutical Company Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Shenyang Sinqi Pharmaceutical Company ESG
Risk Overview
Risk Rating
Updated November, 10, 2022
37.97 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 418
Rank
Percentile
